Stockscreener 앱 받기
3.675
0.94%
-0.035
시간 외 거래:
3.71
0.035
+0.95%
전일 마감가:
$3.71
열려 있는:
$3.8487
하루 거래량:
4,071
Relative Volume:
0.14
시가총액:
$9.93M
수익:
-
순이익/손실:
$-10.69M
주가수익비율:
-0.5189
EPS:
-7.0818
순현금흐름:
$-9.07M
1주 성능:
-1.74%
1개월 성능:
-20.63%
6개월 성능:
-64.99%
1년 성능:
-48.58%
1일 변동 폭
$3.675
$3.8487
1주일 범위
$3.594
$4.04
52주 변동 폭
$3.51
$43.50
인텐시티 테라퓨틱스 Stock (INTS) Company Profile
명칭
Intensity Therapeutics Inc
전화
203-221-7381
주소
1 ENTERPRISE DRIVE, SUITE 430, SHELTON
Compare INTS vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
INTS
Intensity Therapeutics Inc
|
3.675 | 10.62M | 0 | -10.69M | -9.07M | -7.0818 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
인텐시티 테라퓨틱스 주식(INTS)의 최신 뉴스
Why Did INTS Stock Plummet 25% Today? - Stocktwits
Intensity Therapeutics (INTS) Shows Modest Decline, Holds Above Key SupportBear Flag - newsline.com
Intensity_Therapeutics - Westfair Communications
Intensity Therapeutics (INTS) Slips 5.75% as Selling Pressure Intensifies Near Key Support LevelValue Stock Ideas - newsline.com
Intensity Therapeutics Inc (INTS) Stock Price, Quote, News & History - Benzinga
INTS News | INTENSITY THERAPEUTICS INC (NASDAQ:INTS) - ChartMill
INTS Technical Analysis | Trend, Signals & Chart Patterns | INTENSITY THERAPEUTICS INC (NASDAQ:INTS) - ChartMill
Intensity Therapeutics Inc. (INTS) upgraded to buy: Here's why - MSN
INTS | Intensity Therapeutics, Inc. Common Insider Trading - Quiver Quantitative
INTS Q1 2026 Earnings: Narrower-Than-Expected Loss as Pre-Revenue Biotech Advances Clinical PipelineEPS Surprise History - The Legal Advocate
Intensity Therapeutics Inc. (INTS) Upgraded to Buy: Here's Why - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: Daxor (DXR) and Tonix Pharma (TNXP) - The Globe and Mail
INTS Q1 2026 Earnings: EPS Beat Despite Pre-Revenue Status; Shares Edge HigherRevenue Inflection Point - The Legal Advocate
Intensity Therapeutics Inc. (INTS) upgraded to buy: Here's what you should know - MSN
INTS Stock Price, Quote & Chart | INTENSITY THERAPEUTICS INC (NASDAQ:INTS) - ChartMill
Benchmark reiterates Intensity Therapeutics stock rating on clinical progress By Investing.com - Investing.com South Africa
Benchmark reiterates Intensity Therapeutics stock rating on clinical progress - Investing.com India
Intensity Therapeutics shares plunge 30% after $4 million discounted stock offering - MSN
Intensity Therapeutics Recognized with GHP Magazine's 2026 Healthcare & Pharmaceutical Award - ChartMill
Intensity Therapeutics Inc. (INTS) could find a support soon, here's why you should buy the stock now - MSN
How Intensity (INTS) maintains its competitive edge | Q4 2025: Earnings UnderperformMomentum Pick - Newser
Dyne Therapeutics (DYN) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
A. G. P. Maintains Intensity Therapeutics(INTS.US) With Buy Rating, Maintains Target Price $30 - Moomoo
How Intensity (INTS) talent strategy drives results | Q1 2026: Profit Exceeds ViewsAdjusted Earnings Analysis - Newser
Intensity Therapeutics (NASDAQ:INTS) Q1 2026 Results Show EPS Beat Despite No Revenue - ChartMill
8-K: Intensity Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Updatemoomoo - Moomoo
Trial updates frame Intensity Therapeutics (NASDAQ: INTS) Q1 2026 loss - Stock Titan
Intensity Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update - Barchart.com
Intensity Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
INTENSITY THERAPEUTICS ($INTS) Releases Q1 2026 Earnings - Quiver Quantitative
INTS Q1'26 Earnings: EPS estimate is (1.08) USD - TradingView
Why Intensity (INTS) ability to execute stands out (Slow Grind) 2026-05-05Top Analyst Picks - newser.com
Intensity Therapeutics (INTS) price target decreased by 12.76% to 49.98 - MSN
Intensity Therapeutics Inc. (INTS) Could Find a Support Soon, Here's Why You Should Buy the Stock Now - Yahoo Finance Singapore
Intensity Therapeutics (INTS) proxy adds equity plan shares, sets 2026 virtual vote - Stock Titan
[ARS] INTENSITY THERAPEUTICS, INC. SEC Filing - Stock Titan
What Just Happened to Intra-Cellular Therapies (ITCI) Stock - Kavout
Intensity Therapeutics (INTS) price target decreased by 11.32% to 57.29 - MSN
Why Is Retail Going Gaga Over INTS Stocks Today? - MSN
Intensity Therapeutics announces pricing of $4M registered direct offering of common stock - MSN
Intensity Therapeutics (INTS) Institutional Ownership 2026 $INTS - MarketBeat
Intensity Therapeutics Reports 2025 Year End Financial Results and Highlights, and Provides Corporate Update - Aktiellt
인텐시티 테라퓨틱스 (INTS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.60%
0.94%
자본화:
|
볼륨(24시간):